Renalytix gets Nasdaq extension to Oct 25, 2024; transfers to Capital Market

Renalytix plc

Nasdaq Hearings Panel grants until October 25, 2024 to regain compliance with minimum bid price of $1.00.
ADSs transfer from Nasdaq Global Market to Nasdaq Capital Market effective August 27, 2024.
Must also achieve $2.5M minimum stockholders' equity and provide 12-month income projections.
Unaudited cash position $4.7M as of June 30, 2024; cash runway into Q4 2024.
Advanced discussions with stakeholders for funding and refreshed business plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.